UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/662,906	09/15/2003	Rong-Hwa Lin	A0871.70001US00	1268
23628 7590 01/19/2007 WOLF GREENFIELD & SACKS, PC FEDERAL RESERVE PLAZA 600 ATLANTIC AVENUE BOSTON, MA 02210-2206			EXAMINER	
			GAMBEL, PHILLIP	
			ART UNIT	PAPER NUMBER
,			1644	
			<u> </u>	
SHORTENED STATUTORY	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
30 DAYS		01/19/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

10/662906

APPLICATION NO./
CONTROL NO.

FILING DATE
FIRST NAMED INVENTOR /
PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.

EXAMINER

ART UNIT PAPER

1644 01162007

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

Applicant's election of Group I, (A) homomultimeric compounds that binds to at least two PSGL-1 proteins; (D) antigen binding domain of an anti-PSGL-1 antibody; inflammatory disease; and (A) absence of detecting the number of of T cells or detecting the biological activity of the T cells with traverse is acknowledged

It appears that the telephone interview on 10/18/2006 and, in turn, applicant's election have dealt with the inaccuracies or mischaracterizations associated with the nature of the compound (e.g., PSGL-1 versus anti-PSGL-1 antibodies) set forth in the previous Restriction Requirement, mailed 10/4/06.

Other than the election of species, applicant does not appear to traverse the Restriction Requirement.

The requirement is still deemed proper and is therefore made FINAL.

Although applicant elected inflammatory disease, applicant should elect a single disclosed species of an inflammatory disease (e.g. psoriasis, asthma) as the ultimate species, as indicated in the Restriction Requirement, mailed 10/4/06.

Since applicant has received an action on the merits for the originally presented invention, applicant's response is considered non-repsonsive. Since the amendment appears to be a bona fide attempt to be a reply (37 CFR § 1.135(c)), applicant is given a TIME PERIOD of ONE (1) MONTH from the mailing date of this notice within which to re-submit the corrected section which complies with 37 CFR § 1.121 in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel whose telephone number is (571) 272-0844. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841.

The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

PHYLLIP GAMBEL, PH.D. OTO.

PRIMARY EXAMINER

72 1600

1/16/2007